New packaging, Indian Tarceva price for sale, Indian Tarceva, Tarceva Xinxin purchasing agent

Detailed information to purchase
Trade name Tarceva
Generic name Erlotinib hydrochloride tablets
English trade name r
The most common adverse reactions are rash and diarrhea, rash and The incidence of diarrhea was and the median onset of rash was days and the median onset of diarrhea was days, respectively.
The incidence rate is greater than the adverse reactions, including rash, diarrhea, decreased appetite, fatigue, difficulty breathing, cough, nausea, infection, vomiting, stomatitis, itching, dry skin, conjunctivitis, keratoconjunctivitis, abdominal pain.
Pulmonary Toxicity
There are rare reports suggesting that severe interstitial lung disease and even death may occur in patients treated with r or other solid tumors. In randomized controlled studies, the incidence was and this incidence was the same in r treatment and placebo groups reported include pneumonia interstitial pneumonia interstitial lung disease bronchiolitis obliterans pulmonary fibrosis acute respiratory stress syndrome and pulmonary effusion. Symptoms occurred from the day after treatment to more than one month, with a median onset time of days. Most patients often have confounding factors, such as previous chemotherapy/radiotherapy, pulmonary metastasis from existing solid lung disease, or pulmonary infection. When there are new unexplained pulmonary symptoms, such as difficulty breathing, cough, fever, etc., examination and evaluation are required. Once diagnosed, use of r should be stopped and appropriate treatment should be taken.
Hepatotoxicity
Treatment can cause asymptomatic increases in liver transaminases. Therefore, liver function should be reviewed regularly during treatment, including transaminases, bilirubin alkaline phosphatase, etc. If liver function damage is severe, the dose should be reduced. or discontinue medication. Liver damage is often temporary or accompanied by liver metastasis.
Gastrointestinal bleeding is rarely reported and often occurs in patients taking warfarin at the same time. Therefore, patients taking warfarin or other anticoagulants at the same time should monitor their prothrombin time.
Elderly patients
There are no significant differences in safety and pharmacokinetics between young and elderly patients. Therefore, no dose adjustment is recommended when used in elderly patients.
Precautions
This product must be used under the guidance of doctors with experience in the use of such drugs, and can only be used in the national oncology drug clinical trial base or tertiary A hospitals.
Usage and Dosage
The recommended dose of erlotinib alone for the treatment of non-small cell lung cancer is /day, taken at least one hour before or one hour after eating. Tarceva, as an R-mutated targeted drug, is still effective in treating non-small cell lung cancer. However, serious drug resistance will develop after taking it for a period of time, and the effect is less than half of what it was initially.
Others
Specifications]
Storage] Store at ℃, and it is also acceptable between ℃ and ℃.
Packaging] Blister packaging sheet/box.
New package] tablets/box
Validity period] months
Imported drug registration certificate number]
Manufacturer] R
What is the mechanism of action of Tarceva?
The way of action of Tarceva is different from that of chemotherapy. It is a targeted therapy drug that can specifically target tumor cells and inhibit the formation and growth of tumors. A small molecule compound that can inhibit the human epidermal growth factor receptor R signaling pathway. Epidermal growth factor is also called a key component of the R signaling pathway. It plays an important role in the formation and growth of various tumor cells. Tarceva inhibits tumor growth by inhibiting the activity of tyrosine kinase, which is one of the important components in R cells.
Will Tarceva cause common adverse reactions of chemotherapy? Contraindications?
Tarceva is a small molecule compound that can inhibit the human epidermal growth factor receptor R signaling pathway. This mode of action is completely different from traditional chemotherapy, so it will not cause common adverse reactions in chemotherapy. It is only contraindicated for patients who are severely allergic to Tarceva and its excipients.
When will Tarceva be approved by the Food and Drug Administration of the United States and China?
The United States approved Tarceva on 2019 for the treatment of patients with locally progressive or metastatic disease who have failed previous chemotherapy. China approved it on the day of the year.
Drug Donation Project
Purpose
Adhering to the consistent purpose of China Charity Federation, to help low-income people in the case of major diseases, to meet and encourage the material and spiritual needs of patients to fight the disease, and to Help patients with advanced lung cancer receive greater support. Under the leadership of the China Charity Federation and with the strong support of Shanghai Roche Pharmaceutical Co., Ltd., the China Charity Federation Tarceva Charitable Drug Donation Project was launched []
Start date
Year.
Deadline
If drug donation must be stopped due to force majeure or special reasons, the public will be informed in advance through various channels. For patients who have successfully made an appointment and started receiving medicines, these patients will be guaranteed to continue receiving medicines until they meet the criteria for discontinuing medicines.
Target recipients
I know that I have advanced lung cancer and have been evaluated by a designated medical institution and confirmed to be primary advanced non-small cell lung cancer that meets the indications for retreatment with Tarceva. I have undergone at least one systemic chemotherapy before taking the drug. Minimum living allowance patients are entitled to subsistence allowance treatment for at least one year
Non-ministry living allowance patients who have undergone at least one systemic chemotherapy before taking the drug have achieved significant curative effect after continuous months of Tarceva treatment without disease progression, but cannot continue due to financial reasons. Bear the cost of medicines.
*Due to the limited amount of aid, meeting the above conditions does not necessarily mean that you will receive donated medicine.